CPC A61K 39/215 (2013.01) [A61K 31/155 (2013.01); A61K 31/422 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 35/13 (2013.01); A61K 35/66 (2013.01); A61K 35/74 (2013.01); A61K 35/76 (2013.01); A61K 36/06 (2013.01); A61K 39/00 (2013.01); A61K 39/39 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C12N 1/00 (2013.01); C12N 1/02 (2013.01); A61K 2039/543 (2013.01); A61K 2039/55511 (2013.01); C12N 2501/999 (2013.01)] | 17 Claims |
1. A method for producing an immunogenic coronavirus composition, the method comprising:
growing coronaviruses on a cell culture or other appropriate medium;
harvesting the coronaviruses from the cell culture or other appropriate medium;
killing the coronaviruses in the cell culture or other appropriate medium with a dose of methylene blue that is greater than 2.0 micrograms per milliliter so as to damage the RNA and/or the DNA of the coronaviruses, wherein the coronaviruses remain in contact with the methylene blue for a period of time that is sufficient for the methylene blue to penetrate the coronaviruses and attach to RNA or DNA of the coronaviruses and prevent multiplication of the coronaviruses;
separating the dead coronaviruses from a remainder of the cell culture or other appropriate medium using a filter and/or centrifuge;
adding antivirals at non-toxic concentrations to the dead coronaviruses so as to form an immunogenic composition; and
administering the immunogenic composition to a patient in need thereof.
|